Discontinued — last reported Q4 '25
Sherwin-Williams Acquisitions decreased by 100.0% to $0.00 in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 100.0%, from $82.40M to $0.00. Over 4 years (FY 2021 to FY 2025), Acquisitions shows an upward trend with a 54.8% CAGR.
High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.
This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...
Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.
acquisitions| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $400.00K | $0.00 | $185.60M | $400.00K | $211.40M | $415.00M | $376.30M | $300.00K | $22.90M | $0.00 | $241.50M | $0.00 | $0.00 | $0.00 | $78.90M | $82.40M | $39.00M | -$2.10M | $1.09B | $0.00 |
| QoQ Change | — | -100.0% | — | -99.8% | >999% | +96.3% | -9.3% | -99.9% | >999% | -100.0% | — | -100.0% | — | — | — | +4.4% | -52.7% | -105.4% | >999% | -100.0% |
| YoY Change | — | — | — | — | >999% | — | +102.7% | -25.0% | -89.2% | -100.0% | -35.8% | -100.0% | -100.0% | — | -67.3% | — | — | — | >999% | -100.0% |